A
Agios Pharmaceuticals, Inc. (AGIO)
NMS – Real Time Price. Currency in USD
28.42
+0.43 (1.54%)
At close: May 12, 2026, 4:00 PM EDT
28.42
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
28.42
+0.43 (1.54%)
At close: May 12, 2026, 4:00 PM EDT
28.42
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.19 | 6.05 | 10 | |
| Quick ratio | 13.59 | 5.63 | 10 | |
| Debt to Equity | 0.03 | 0.30 | 9.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 14M | 27M | 36M | 54M | 66M |
| Gross Profit | -6M | 17M | 27M | 43M | 54M |
| Operating Income | -389M | -391M | -426M | -472M | -476M |
| Net Income | -232M | -352M | 674M | -413M | -423M |
| EBITDA | -370M | -385M | -420M | -467M | -470M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 107.41 | 16.75 | 9.5 |
| Next quarter | 157.27 | 17.37 | 9.5 |
| Current year | 122.49 | 13.91 | 9.0 |
| Next year | 116.27 | 23.68 | 10 |
| Weighted average score | 9.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 3.9 | 8.26 | 9.14 | -22.96 | 4.3 |
| Y/Y | 137.75 | -10.99 | -9.02 | -6.61 | 3.3 |
| 3y average | 57.49 | 26.07 | 24.36 | -7.54 | 7.8 |
| 5y average | 434.09 | 20.1 | 123.46 | -6.84 | 7.8 |
| Weighted average score | 5.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $113.6M significantly exceed its total debt $35.7M, ensuring strong financial flexibility
Total current assets $834.8M exceed Total current liabilities $58.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$119.7M limits the company's ability to reinvest or pay down debt